Clinical Trials Directory

Trials / Completed

CompletedNCT00183235

Aripiprazole Effects on Alcohol Reactivity and Consumption

Effectiveness of Aripiprazole to Reduce Craving for Alcohol and Drinking Under Natural Observation, During Cue Induced Brain Imaging, and During a Motivated Free Choice Drinking Procedure Compared to Placebo

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (planned)
Sponsor
Medical University of South Carolina · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving compared to placebo.

Detailed description

Non-treatment seeking individuals meeting criteria for alcohol dependence (N=30) will be recruited through advertisement and paid for their participation. Alcoholics, after baseline evaluation, will be assigned through urn randomization to one of two experimental groups in which they will receive either aripiprazole (up to 15 mg/day) or an identical placebo. Subjects will take the study drug or placebo for 8 days (day 1-6 being the natural observation period). After a minimum of 24 hours of abstinence from alcohol (day 7-8) they will undergo an alcohol administration (priming dose) and motivated free choice drinking procedure (on day 8). Alcoholic subjects will receive a brief counseling session at the end of the study to enhance their awareness of problem drinking and to motivate them to seek treatment. Referral for treatment will be offered. Each subject will undergo a functional MRI brain scan with cue stimulation on day 7, on the evening before the alcohol administration paradigm. fMRI brain imaging technology will be used to determine if alcoholics treated with aripiprazole differ in alcohol cue-induced activity in the nucleus accumbens. It is hypothesized that aripiprazole will reduce nucleus accumbens activation to alcohol cues compared to placebo.

Conditions

Interventions

TypeNameDescription
DRUGaripiprazole (up to 15 mg/day) for 8 days

Timeline

Start date
2005-06-01
Completion
2006-02-01
First posted
2005-09-16
Last updated
2010-05-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00183235. Inclusion in this directory is not an endorsement.